Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
New to Comunitee?

or Sign Up with Email



FEB 25, 2013 - Yahoo! News

A Must Read - Share

Royalty Pharma may offer $6.6 billion bid for Elan

DUBLIN (Reuters) - U.S. investment firm Royalty Pharma has made a $6.6 billion approach to Irish drugmaker Elan, targeting royalty rights for multiple sclerosis treatment Tysabri worth hundreds of millions of dollars annually. Elan said earlier this month it was to sell its 50 percent interest in Tysabri for $3.25 billion plus future royalty payments to U.S. partner Biogen Idec, and then reinvent itself with a series of acquisitions. Those royalty payments on future Tysabri sales, which rose 8 percent to $1.63 billion in 2012, will be 12 percent for the first year and 18 percent thereafter. ... Read More

Tags: Royalty Pharma may offer $6.6 billion bid for Elan,  Multiple Sclerosis Latest News